In recent years, persistent disparities in cancer-related outcomes have heightened calls for inclusion of racial and ethnic minority individuals and other underrepresented populations in prospective clinical research. Researchers are keenly aware of the imperative to increase enrollment of diverse patient populations, but lack of trust, lack of awareness of clinical trial opportunities, limited access to care, and ineffective communication contribute to underenrollment. In addition to poor clinical trial accrual that has stagnated for more than a decade with fewer than 1 in 20 adult patients with cancer enrolled in ongoing studies and nearly 1 in 5 adult cancer clinical trials failing to reach completion, largely owing to poor accrual, it is evident that the current system of recruitment is not optimized to bring medical advances and prospective treatments to patients.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Culbert M, Oladeru OT. Clinical Trial Enrollment of Racial, Ethnic, and Underrepresented Groups—Leveraging a Digital Infrastructure. JAMA Oncol. 2021;7(10):1447–1448. doi:10.1001/jamaoncol.2021.2680
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.